Dainippon Sumitomo Pharma Biomedical To Market Serum Free STK2
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma's biopharma subsidiary, Hiroshima-based DS Pharma Biomedical will market STK2, a human mesenchymal stem cell made by serum-free culture media on May 12. The company obtained the serum-free media technology from Twocell, a Japanese regenerative medicine venture company also based in Hiroshima. Currently, fetal bovine serum or human serum is needed to culture human mesenchymal stem cells. The company comments that the product will contribute greatly to the regenerative medicine area. (Click here for more - Japanese language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.